Cutting edge genomics technologies to power and enhance immuno-oncology (IO) trials where reporting transcriptional response pairs a person to therapy without multiple biopsies.
MSI assay for sensitive detection of 5 mononucleotide repeat markers in tumor FFPE specimens.
Gene expression and analysis for detection of 11 Immune Landscape Signatures.
Best practices for rapid test development and regulatory approvals.
Using anatomic pathology for biomarker development in clinical trials can help predict and assess how a patient will respond to immuno-oncology therapies
Measurement of Residual Disease for improved oncology trial outcomes - what factors make an MRD test most effective plus explore the pros and cons of various MRD measurement approaches.
Exploring the challenges with the diverse clinical biomarker requirements.
Advances in precision medicine lead to new trends in immunotherapy.
Overcoming hurdles in a regulated setting.
CRO mergers affect the agility and speed of operations and may hamper efforts to bring in new technologies but at the same time can add significant value to both the pharmaceutical industry and the patients who depend on the life-saving medicines it produces.
|
|
|
|
|
|
|
|
|